Executive summary
Introduction
Definitions and methodology
> Scope and coverage
> Glossary
> Methodology
> Patents
> Indexing by indication
> Indexing by phase of development
> Nomenclature
Reference products
> Top20 Reference Products
Biosimilars in development
> Biosimilars by earliest potential launch date — US & EU
> Biosimilars by class and earliest potential launch date in the US (total number)
> Biosimilars by class and earliest potential launch date in the EU (total number)
> Biosimilar developers countries and regions
> Biosimilars in development by drug class
> Leading biosimilar companies - number of biosimilar products in portfolio
> Biosimilar development pipelines by compound class and therapy area
Biosimilar development pipelines by compound class
> Immunomodulators
> Interferons
> mAb Immunomodulators
> Cytotoxic mAbs
> Erythropoietin
> G-CSF
> Insulins
> Other Hormones (excluding insulins)
Biosimilar development pipelines by therapy area
> Endocrine and metabolic disorders
> Haematology
> Infectious and Parasitic Disease
> Musculoskeletal disorders
> Neurology
> Neuromuscular diseases
> Obstetrics/gynaecology
> Oncology
> Ophthalmology
Biobetters in development
> Biobetter developments by compound class and therapy area
> Biobetter development by therapy area and stage
> Biobetters by class and earliest potential launch in the US
> Biobetters by class and earliest potential launch in the EU
> Biobetter developers by compound class
Biobetter development pipeline by compound class
> I
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |